CAR-T therapy collects a patient’s own T-cells, genetically reprograms them in a lab to carry a “chimeric antigen receptor” that targets CD19 (a protein on B-ALL cells), grows them into millions, and infuses them back. The engineered cells then hunt down and destroy the leukemia. Tisagenlecleucel (Kymriah) was the first FDA-approved CAR-T therapy (2017), for B-ALL up to age 25 that is refractory or in a second or later relapse. It can produce durable remissions when other treatments have failed.
The patient’s T-cells are collected (leukapheresis), engineered and grown over a few weeks, then — after a short “lymphodepleting” chemotherapy — infused back as a single dose, usually at a certified center with inpatient monitoring.
Close monitoring for several weeks for cytokine release syndrome and neurologic effects, typically beginning in hospital. Many patients reach remission; some still need a transplant. Long-term follow-up tracks B-cell recovery and infection risk.